Amylyx Pharmaceuticals Inc.

Home
United States
Cambridge, MA
Amylyx Pharmaceuticals Inc.

Ushering in a new era for treating diseases with high unmet needs

02/19/2026

We were honored to host Cindy and her husband Ray at our recent Anchor Week. They shared with us the partnership, determination, and hope that have been critical throughout Cindy's journey with post-bariatric hypoglycemia (PBH).

The communities we collaborate with drive us forward, and Cindy and Ray brought our work to life in such a powerful way. Thank you for speaking with !

02/17/2026

Post-bariatric hypoglycemia (PBH) is thought to be caused by changes in hormonal and glycemic patterns, including an excessive glucagon-like peptide-1 (GLP-1) response, leading to repeated episodes of low blood sugar (also know as hypoglycemia) that impair quality of life.

Over time, repeated episodes of hypoglycemia can lead to hypoglycemia unawareness, a condition where the body does not produce the typical early warning signs of hypoglycemia until blood sugar levels drop dangerously low. Learn more about PBH on our website at https://bit.ly/4tCBxTD

02/12/2026

What does it mean to be Rooted in Connection?

Amylyx values the connections between our company and the communities we serve, between questions and solutions, and between insights and actions. We see a path between where we are and where we need to be. Our work, our motivation, and the core values that guide us are deeply interwoven.

Learn more about our company: https://bit.ly/4qsj2OF

02/11/2026

Last week, gathered at headquarters for Anchor Week, a special time for collaboration and connection across our hybrid-remote team and with guests from the broader community. Check out some of the highlights below.

02/06/2026

Raquel’s path to a diagnosis of started at 4 years old when she was diagnosed with diabetes. She started losing her vision at 5 years old. In honor of upcoming , hear her story on this rare condition that affects approximately 3,000 people in the U.S. at https://bit.ly/3Zmju65

02/03/2026

ALS is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neuron death in the brain and spinal cord.

Calpain-2, when overactive, may play an important role in how ALS and other neurodegenerative diseases progress. In research studies, blocking calpain-2 activity has been shown to help protect nerve fibers and support neuron health. Learn more about the connection between calpain-2 and ALS on our website at https://bit.ly/3OhjKkm.

01/30/2026

Wolfram syndrome is a rare genetic disorder that affects approximately 3,000 people living in the U.S. with no approved treatment options.

Common manifestations of Wolfram syndrome include insulin-requiring diabetes mellitus, vision loss, diabetes insipidus, hearing loss, neurogenic bladder, impaired balance and coordination, and difficulty breathing that can progress to respiratory failure. Learn more about Wolfram syndrome on our website at: https://bit.ly/3Zbrhnf

01/26/2026

Our team is growing! Amylyx has an audacious mission to usher in a new era for treating diseases with high unmet needs. If you share our passion and are determined to tackle some of medicine’s toughest challenges, check out the opportunities here and apply: https://www.amylyx.com/open-positions

01/23/2026

Community voices drive innovation. To change the trajectory of diseases with high unmet needs, we first listen to those impacted.

Jessica is a passionate mother, case manager, and advocate with post-bariatric (PBH). She shared her story – and unwavering determination – with us to raise : https://amylyx.com/jessicas-PBH-story

If you’re interested in sharing your experience with PBH, email pbhcommunity@amylyx.com.

01/15/2026

Post-bariatric hypoglycemia (PBH) is a rare, chronic condition with no FDA-approved treatments. Among the roughly two million people who have had Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy in the past decade, an estimated 160,000 are living with PBH today.

The condition can cause debilitating low blood sugar episodes when the brain does not receive enough glucose. PBH can be difficult to diagnose as symptoms, such as brain fog, fatigue, sweating, blurred vision, and dizziness, can be non-specific, vary in severity, and/or be mistaken for dumping syndrome. Learn more about PBH on our website at https://www.amylyx.com/

01/08/2026

Today, we announced the nomination of an investigational, long-acting GLP-1 receptor antagonist as our new development candidate, identified in collaboration with Gubra A/S. Learn more about this exciting update: https://bit.ly/3LCCZEb

01/05/2026

We have an audacious mission to develop novel therapies for high unmet needs. Where others see challenges, we see opportunities that members of like Natalia pursue with urgency and unwavering commitment to the communities we serve.

View our open positions and apply today: https://www.amylyx.com/careers

Address

55 Cambridge Parkway, Suite 6W
Cambridge, MA
02142

Website

https://www.amylyx.com/, https://www.amylyx.com/social-media-guidelines, https://www.amylyx.com/privacy-notice

Alerts

Be the first to know and let us send you an email when Amylyx Pharmaceuticals Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Amylyx Pharmaceuticals Inc.:

Want your practice to be the top-listed Clinic in Cambridge?